World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
41857
World Ranking
13877
National Ranking
7045

Overview

Saad Z. Usmani is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on hematology and oncology, with a strong emphasis on multiple myeloma and related therapeutic approaches.

The scientist's work spans several fields, including Medicine and Biochemistry, Genetics, and Molecular Biology. Subfields of study include Hematology, Oncology, Molecular Biology, Genetics, and Immunology. Their research topics cover multiple myeloma research and treatments, protein degradation and inhibitors, CAR-T cell therapy research, peptidase inhibition and analysis, chronic lymphocytic leukemia research, monoclonal and polyclonal antibodies research, and cancer treatment and pharmacology.

Some of the recent significant papers authored or co-authored by Saad Z. Usmani include:

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study, 2021, The Lancet
  • Teclistamab in Relapsed or Refractory Multiple Myeloma, 2022, New England Journal of Medicine
  • Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up, 2022, Journal of Clinical Oncology
  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches, 2020, Leukemia
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, 2020, The Lancet

Frequent co-authors collaborating with Saad Z. Usmani include:

  • Alexander M. Lesokhin
  • Kylee Maclachlan
  • Sham Mailankody
  • Urvi A. Shah
  • Neha Korde

The most common venues for publishing their research are Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Blood Cancer Journal, and Transplantation and Cellular Therapy.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesus G Berdeja;Deepu Madduri;Saad Z Usmani;Andrzej Jakubowiak

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

    Thierry Facon;Shaji Kumar;Torben Plesner;Robert Z Orlowski

  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

    Sagar Lonial;Hans C Lee;Ashraf Z Badros;Suzanne Trudel

  • IMWG consensus on risk stratification in multiple myeloma

    W J Chng;A Dispenzieri;C-S Chim;R Fonseca

  • Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

    Ujjawal H. Gandhi;Robert F. Cornell;Arjun Lakshman;Zhubin J. Gahvari

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Saad Z. Usmani;Brendan M. Weiss;Torben Plesner;Nizar J. Bahlis

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    C. Fernández De Larrea;R. A. Kyle;B. G.M. Durie;H. Ludwig

  • Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

    Saad Z. Usmani;Christoph Heuck;Alan Mitchell;Jackie Szymonifka

  • Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

    Meletios A. Dimopoulos;Jens Hillengass;Saad Usmani;Elena Zamagni

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

    Meletios Dimopoulos;Hang Quach;Maria-Victoria Mateos;Ola Landgren

  • International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Jens Hillengass;Saad Usmani;S Vincent Rajkumar;Brian G M Durie

  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    Nina Shah;Ajai Chari;Emma Scott;Khalid Mezzi

  • Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

    Antonio Palumbo;Sara Bringhen;Shaji K Kumar;Giulia Lupparelli

  • CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

    Niels W.C.J. van de Donk;Saad Z. Usmani

Frequent Co-Authors

Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Shaji Kumar
Shaji Kumar Mayo Clinic
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Frits van Rhee
Frits van Rhee University of Arkansas for Medical Sciences
Parameswaran Hari
Parameswaran Hari Medical College of Wisconsin
Sagar Lonial
Sagar Lonial Emory University
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Paul G. Richardson
Paul G. Richardson Harvard University
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the healthcare field goes beyond traditional medical school paths. Many students consider flexible online programs that offer faster or more affordable routes to rewarding medical careers. For registered nurses seeking to advance their education, finding what is the cheapest rn to bsn program online is an important step, helping to balance cost and quality.

Those with a bachelor’s degree in a non-nursing field may look into direct entry msn programs for non nurses online. These programs offer a fast track into advanced nursing roles by leveraging your previous degree.

If you’re in search of less competitive entry requirements, research is available on the easiest nursing schools to get into, making it possible for more students to begin their healthcare education journey without high barriers.

Alternatively, a career in healthcare administration is also accessible through online education. For those interested in supportive roles, exploring the best online medical billing and coding schools can open doors to vital positions with strong job prospects.

Best Scientists Citing Saad Z. Usmani

Trending Scientists